AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12971709 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized psychomotor fitness programme
Number of subjects: 199
Study 10897124 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD
Number of subjects: 67
Study 10897124 — intervention group
Group type: COMPARATOR
Intervention: MOPPEBVCyED
Number of subjects: 67
Study 8622245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (acebutolol)
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (amlodipine)
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-antagonist (doxazosin)
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 902
Study 8622245 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 902
Study 1383173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast computed tomography (UFCT) videotape
Number of subjects: 180
Study 1383173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac dissection
Number of subjects: 180
Study 1383173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac dissection and UFCT videotape
Number of subjects: 180
Study 1383173 — intervention group
Group type: COMPARATOR
Intervention: No instruction (control group)
Number of subjects: 180
Study 6319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 21
Study 31655509 — intervention group
Group type: EXPERIMENTAL
Intervention: pSS group
Number of subjects: 36
Study 31655509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 30466402 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (8.3 μg or 5 U)
Number of subjects: 51
Study 30466402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27301730 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified chevron osteotomy
Number of subjects: 84
Study 27301730 — intervention group
Group type: COMPARATOR
Intervention: Scarf osteotomy
Number of subjects: 84
Study 27301730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 84
Study 25082573 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 0
Study 25082573 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study 25082573 — intervention group
Group type: EXPERIMENTAL
Intervention: sSS-based SS II
Number of subjects: 0
Study 22759406 — intervention group
Group type: EXPERIMENTAL
Intervention: Back‐Shu and Front‐Mu acupoints of Large Intestine meridians (Shu‐Mu points group)
Number of subjects: 700
Study 22759406 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Sea and Lower He‐Sea acupoints of Large Intestine meridians (He points group)
Number of subjects: 700
Study 22759406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining used Back‐Shu, Front‐Mu, He‐Sea, and Lower He‐Sea acupoints of Large Intestine meridians (Shu‐Mu‐He points group)
Number of subjects: 700
Study 22759406 — intervention group
Group type: COMPARATOR
Intervention: Mosapride Citrate (control group)
Number of subjects: 700
Study 20472091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria (LN strains)
Number of subjects: 95
Study 20472091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 18076268 — intervention group
Group type: EXPERIMENTAL
Intervention: Including the contribution of body mass in force output (IBM)
Number of subjects: 12
Study 18076268 — intervention group
Group type: EXPERIMENTAL
Intervention: Including the contribution of the mass of body less the mass of the shanks and feet in force output (IBMS)
Number of subjects: 12
Study 18076268 — intervention group
Group type: COMPARATOR
Intervention: Excluding the contribution of body mass in force output (EBM)
Number of subjects: 12
Study 15871654 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) methods applied to drug utilization patterns
Number of subjects: 0
Study 15871654 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical research
Number of subjects: 0
Study 15871654 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical care
Number of subjects: 0
Study 12196660 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g Semmes‐Weinstein monofilament (touch/pressure sensation)
Number of subjects: 0
Study 12196660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurothesiometer (vibration perception threshold)
Number of subjects: 0
Study 11083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (4 mg in 5 minutes at admission, followed by 6 mg/hr over 24 hours)
Number of subjects: 62
Study 11083193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 62
Study 9437273 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol-dextropropoxyphene
Number of subjects: 2231
Study 9437273 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 2231
Study 8123120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 300 mg weekly and proguanil 100 mg daily
Number of subjects: 58
Study 8123120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 300 mg weekly and proguanil 200 mg daily
Number of subjects: 58
Study 8123120 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil 200 mg daily
Number of subjects: 58
Study 3021499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg q.i.d.
Number of subjects: 0
Study 3021499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2 mg q.i.d.
Number of subjects: 0
Study 3021499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29406429 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐TasP adherence and sexual health intervention
Number of subjects: 500
Study 29406429 — intervention group
Group type: COMPARATOR
Intervention: General health control intervention
Number of subjects: 500
Study 27084751 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPregn@ncy (Personal Health Record)
Number of subjects: 4500
Study 27084751 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard maternity care without PHR)
Number of subjects: 4500
Study 25151205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g infusion)
Number of subjects: 499
Study 25151205 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) and Metronidazole (500 mg)
Number of subjects: 499
Study 25151205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 499
Study 25151205 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 499
Study 22490901 — intervention group
Group type: EXPERIMENTAL
Intervention: HNIPPV plus tiotropium bromide and doxofylline tablets
Number of subjects: 44
Study 22490901 — intervention group
Group type: COMPARATOR
Intervention: Control group (tiotropium bromide, doxofylline tablets, and low-flow inhalation of oxygen)
Number of subjects: 44
Study 20123769 — intervention group
Group type: EXPERIMENTAL
Intervention: WBT + HOT
Number of subjects: 56
Study 20123769 — intervention group
Group type: COMPARATOR
Intervention: WBT
Number of subjects: 56
Study 18589554 — intervention group
Group type: EXPERIMENTAL
Intervention: Daidzein dripping pills (50 mg)
Number of subjects: 20
Study 18589554 — intervention group
Group type: COMPARATOR
Intervention: Daidzein tablets (50 mg)
Number of subjects: 20
Study 16078335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg patch
Number of subjects: 172
Study 16078335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 12375713 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 microg, 2 inhalations via MDI with spacer)
Number of subjects: 10
Study 12375713 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, 2 inhalations via MDI or Diskus)
Number of subjects: 10
Study 12375713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MDI with spacer)
Number of subjects: 10
Study 10355006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of first permanent molars on one side
Number of subjects: 74
Study 10355006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of unsealed side after three months
Number of subjects: 74
Study 8522784 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral effects during work hours
Number of subjects: 100
Study 1874224 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise rising propofol infusion regime of 0.24, 0.6 and 1.5 mg kg‐1 h‐1 for 75 min (25 min at each infusion rate)
Number of subjects: 6
Study 1874224 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (as a control)
Number of subjects: 6
Study 31808410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50mg
Number of subjects: 480
Study 31808410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg
Number of subjects: 480
Study 31808410 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Number of subjects: 480
Study 31808410 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Number of subjects: 480
Study 28463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene 0.45 mg/20 mg
Number of subjects: 0
Study 28463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene 0.625 mg/20 mg
Number of subjects: 0
Study 28463874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24748629 — intervention group
Group type: EXPERIMENTAL
Intervention: blisibimod 200 mg once-weekly (QW)
Number of subjects: 547
Study 24748629 — intervention group
Group type: EXPERIMENTAL
Intervention: blisibimod
Number of subjects: 547
Study 24748629 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 547
Study 23378102 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluorothymidine (FLT)
Number of subjects: 30
Study 23378102 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluorodeoxyglucose (FDG)
Number of subjects: 30
Study 20237929 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (daily locally applied mud‐packs and bicarbonate‐sulphate mineral bath water)
Number of subjects: 30
Study 19661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (adenosine receptor antagonist)
Number of subjects: 18
Study 19661449 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 19661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha‐adrenoceptor antagonist)
Number of subjects: 18
Study 19661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phentolamine and aminophylline administration
Number of subjects: 18
Study 19661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous adenosine
Number of subjects: 18
Study 17872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision rules only
Number of subjects: 40
Study 17872717 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 40
Study 17872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen test only
Number of subjects: 40
Study 17872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision rules and antigen test combined
Number of subjects: 40
Study 15471841 — intervention group
Group type: EXPERIMENTAL
Intervention: AAPM/Sgouros method blood model approach to marrow dosimetry
Number of subjects: 22
Study 15471841 — intervention group
Group type: COMPARATOR
Intervention: Participating institution calculation
Number of subjects: 22
Study 15471841 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory value
Number of subjects: 22
Study 11552199 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee immobilized (KI)
Number of subjects: 10
Study 11552199 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee and arm immobilized (KAI)
Number of subjects: 10
Study 11552199 — intervention group
Group type: COMPARATOR
Intervention: Arm immobilized (AI)
Number of subjects: 10
Study 9926057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community mental health service
Number of subjects: 0
Study 9926057 — intervention group
Group type: COMPARATOR
Intervention: Standard community mental health service
Number of subjects: 0
Study 8072714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 120 mg via PCA pump (20 mg initial bolus, 2 mg demand bolus, 5 min lock‐out time, 4 mg/h continuous infusion, 48 mg maximum dose not including initial bolus)
Number of subjects: 28
Study 8072714 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg IM every 6 hours
Number of subjects: 28
Study 3401025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation at fluences of 3.0, 3.7, or 4.4 J/cm2
Number of subjects: 6
Study 3401025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation at fluences of 3.7 or 4.4 J/cm2
Number of subjects: 6
Study 3401025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation
Number of subjects: 6
Study 30792141 — intervention group
Group type: EXPERIMENTAL
Intervention: Beefsteak tomato (250 g, 2 hours before sleep for 8 weeks)
Number of subjects: 36
Study 30792141 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 31686648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical examination with supplemental transoral ultrasound
Number of subjects: 88
Study 31686648 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical examination (control)
Number of subjects: 88
Study 28464700 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Heart Rate (IHR)
Number of subjects: 108
Study 28464700 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Fitness (HF)
Number of subjects: 108
Study 28464700 — intervention group
Group type: EXPERIMENTAL
Intervention: Whats My Heart Rate (WMH)
Number of subjects: 108
Study 28464700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiio Version (CAR)
Number of subjects: 108
Study 28464700 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 108
Study 25209170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 242
Study 24059377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided subacromial injections
Number of subjects: 98
Study 21444699 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 180 mg
Number of subjects: 10
Study 21444699 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 240 mg once daily for 7 days
Number of subjects: 10
Study 21444699 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 240 mg
Number of subjects: 10
Study 21444699 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution)
Number of subjects: 10
Study 18193962 — intervention group
Group type: EXPERIMENTAL
Intervention: New glass ionomer adhesive with 10% polyacrylic acid conditioning
Number of subjects: 60
Study 18193962 — intervention group
Group type: EXPERIMENTAL
Intervention: New glass ionomer adhesive with 37% phosphoric acid conditioning
Number of subjects: 60
Study 18193962 — intervention group
Group type: COMPARATOR
Intervention: Composite adhesive with 37% phosphoric acid conditioning (control)
Number of subjects: 60
Study 16861547 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCT scanner
Number of subjects: 1000
Study 16861547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-detector scanner
Number of subjects: 1000
Study 16861547 — intervention group
Group type: COMPARATOR
Intervention: Screening efficacy
Number of subjects: 1000
Study 16861547 — intervention group
Group type: COMPARATOR
Intervention: Screening recommendation
Number of subjects: 1000
Study 14960118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonification of range information using a point laser range sensor
Number of subjects: 0
Study 10785875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 100
Study 10785875 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study 8620638 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy program (Group 2) designed to strengthen upper and lower limbs and improve knee range of motion
Number of subjects: 30
Study 8620638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular conditioning program (Group 3) consisting of arm ergometry, cycle ergometry, aquatic exercises, and aerobic activity
Number of subjects: 30
Study 8620638 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1) with no preoperative physical therapy
Number of subjects: 30
Study 1458033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg bid)
Number of subjects: 20
Study 1458033 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study 6393460 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose oral contraceptive
Number of subjects: 0
Study 6393460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptive
Number of subjects: 0
Study 29325799 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of HCY ≥ 14.65 μmol/l and hs-CRP ≥ 1.90 mg/l
Number of subjects: 598
Study 29325799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCY and hs-CRP
Number of subjects: 598
Study 27687366 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Infiltration (LAI)
Number of subjects: 156
Study 27687366 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SPIN)
Number of subjects: 156
Study 27687366 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 156
Study 24618303 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast tablets and fluticasone propionate nasal spray (n = 64)
Number of subjects: 128
Study 24618303 — intervention group
Group type: COMPARATOR
Intervention: Placebo and fluticasone propionate
Number of subjects: 128
Study 22788915 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 145
Study 22788915 — intervention group
Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 145
Study 19713953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Water fountains installed and lessons to promote water consumption
Number of subjects: 2950
Study 19713953 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 2950
Study 19713953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Water consumption promotion
Number of subjects: 2950
Study 18700451 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse Diode Laser Trabeculoplasty (MDLT)
Number of subjects: 26
Study 18700451 — intervention group
Group type: COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Number of subjects: 26
Study 15960404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 20
Study 15960404 — intervention group
Group type: COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 20
Study 12823079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 100 mg daily)
Number of subjects: 207
Study 12823079 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (100 to 200 mg daily)
Number of subjects: 207
Study 12823079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 207
Study 12823079 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 207
Study 11114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of alpha-linolenic acid (ALA)
Number of subjects: 266
Study 11114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of linoleic acid (LA)
Number of subjects: 266
Study 11114683 — intervention group
Group type: EXPERIMENTAL
Intervention: LA/ALA ratio
Number of subjects: 266
Study 11114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of CE ALA
Number of subjects: 266
Study 8644683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE)
Number of subjects: 2
Study 8644683 — intervention group
Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 2
Study 1996743 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (weekly for four weeks)
Number of subjects: 50
Study 1996743 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 50
Study 1996743 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and No drug (both groups)
Number of subjects: 50
Study 6468470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aspirin
Number of subjects: 40
Study 6468470 — intervention group
Group type: COMPARATOR
Intervention: 1 g paracetamol
Number of subjects: 40
Study 30824428 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 0
Study 30824428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28289041 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA/PHEN
Number of subjects: 335
Study 28289041 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 335
Study 25556022 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss surgery (WLS)
Number of subjects: 242
Study 23339731 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 115
Study 23339731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 21333876 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser (Group A)
Number of subjects: 87
Study 21333876 — intervention group
Group type: EXPERIMENTAL
Intervention: VisuMax femtosecond laser (Group B)
Number of subjects: 87